Frederick L. Baehner

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT013: Whole-exome sequencing tumor-informed circulating tumor DNA detection after completion of neoadjuvant treatment predicts non-pCR and distant recurrence in patients with early triple-negative breast cancer (TNBC) — Results from a sub-study of the NSABP B-59/GBG-96-GeparDouze Trial

  Cancer Research · 2026-04-17

• Characterization of ESR1 alterations in patients with breast and gynecologic cancers

  Breast Cancer Research · 2026-01-19 · 1 citations

• Additional file 1 of Characterization of ESR1 alterations in patients with breast and gynecologic cancers

  Figshare · 2026-01-01

• Characterization of ESR1 alterations in patients with breast and gynecologic cancers

  Figshare · 2026-01-01

• Additional file 1 of Characterization of ESR1 alterations in patients with breast and gynecologic cancers

  Open MIND · 2026-01-01

• Characterization of ESR1 alterations in patients with breast and gynecologic cancers

  Figshare · 2026-01-01

• Tumor-informed Assessment of Minimal Residual Disease Using Circulating Tumor DNA (ctDNA) in Breast and Colorectal Cancers

  The Journal of Liquid Biopsy · 2025-11-01

• Comprehensive genomic profiling of over 10,000 advanced solid tumors

  Oncotarget · 2025-07-25 · 2 citations

• The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: The β-CORRECT study.

  Journal of Clinical Oncology · 2025-05-28

• Enhancing recurrence detection in stage III colorectal cancer patients through molecular residual disease test-guided surveillance: A modeling study.

  Journal of Clinical Oncology · 2025-05-28

• HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

  Breast Cancer Research · 2025-02-14 · 7 citations

• Circulating tumor DNA as a marker of recurrence risk in stage III colorectal cancer: The α-CORRECT study.

  Journal of Clinical Oncology · 2025-01-27

• Circulating Tumor DNA as a Marker of Recurrence Risk in Stage III Colorectal Cancer: The α‐CORRECT Study

  Journal of Surgical Oncology · 2025-01-25 · 7 citations

• Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer

  Journal of Clinical Oncology · 2024-12-02 · 13 citations

• Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis

  JNCI Journal of the National Cancer Institute · 2024-10-18 · 3 citations

• Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.

  UNC Libraries · 2024-10-09

• Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

  European Journal of Cancer · 2024-08-14 · 4 citations

• CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).

  Journal of Clinical Oncology · 2024-08-10

• Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data

  ESMO Open · 2024-08-01 · 6 citations

• Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival

  NEJM Evidence · 2024-07-23 · 17 citations